Fecha de recepción: 14/11/2017 – Fecha de aceptación: 08/02/2018
Serrano-Giménez R1, Fobelo-Lozano MJ1,García-Bernal A2
1 Servicio de Farmacia
2 Servicio de Oftalmología
Hospital Universitario de Valme. Sevilla (España)
Reyes Serrano Giménez
Hospital Nuestra Señora de Valme
(Servicio de Farmacia)
Avenida Bellavista, s/n
Correo electrónico: email@example.com
Peripheral ulcerative keratitis (PUK) is a disorder consisting of an area of destructive inflammation at the margin of the corneal stroma. It is associated with an epithelial defect, presence of stroma inflammatory cells and progressive stromal degradation and thinning. This can lead to an ocular perforation and important visual loss. The most frequent cause is associated wtih concomitant connective tissue diseases, especially rheumatoid arthritis and to a lesser extent polyarteritis nodosa and polychondritis. In many cases, the disease may be resistant to high doses of systemic corticosteroids and immunosuppressants; in these cases of failure to these treatments, it is described the use of biological therapy.
It is presented (as off-label use) the use and effectiveness of infliximab in a patient affected by PUK; likewise, the results of the cases and the series of cases currently published on the subject are evaluated.
Key Words: Infliximab, keratolysis, anti-TNF alpha, keratitis, corneal ulcer.